Author

B. P. Sharpe

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:imaging· 1 Assay:proteomics· 1

Frequent Co-Authors

J. Harrington· 2 shared M. Rose-Zerilli· 2 shared T. J. Underwood· 2 shared A. A. Ritchie· 1 shared A. Cowie· 1 shared A. Hayden· 1 shared A. M. Grabowska· 1 shared A. Manousopoulou· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Harrington

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Patient-Derived Tumor Organoid and Fibroblast Assembloid Models for interrogation of the tumor microenvironment in Esophageal Adenocarcinoma

B. P. Sharpe, L. A. Nazlamova, C. Tse, D. A. Johnston, R. Blyth, O. J. Pickering, B. Grace, J. Harrington, R. Rajak, M. Rose-Zerilli, Z. S. Walters, T. J. Underwood

The paper develops assembloid models of esophageal adenocarcinoma using tumor organoids and fibroblasts to study the tumor microenvironment.

bioRxiv · Jan 2, 2024Cancer Biology

Modulation of the tumour promoting functions of cancer associated fibroblasts by phosphodiesterase type 5 inhibition increases the efficacy of chemotherapy in human preclinical models of esophageal adenocarcinoma.

A. Hayden, A. Manousopoulou, A. Cowie, R. Walker, B. P. Sharpe, J. Harrington, F. Izadi, E. Kyle, J. H. Saunders, S. L. Parsons, A. A. Ritchie, P. A. Clarke, P. Collier, S. D. Garbis, M. Rose-Zerilli, , T. J. Underwood

This study shows that PDE5 inhibition reduces CAF tumor-promoting effects and enhances chemotherapy efficacy in EAC models.

bioRxiv · Apr 21, 2020 · PreprintCancer Biology